Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices 36563 

Maryland 20852. Phone: 240–453–6173; 

email: COVID19HETF@hhs.gov. 

SUPPLEMENTARY INFORMATION: 

Background: The COVID–19 Health 

Equity Task Force (Task Force) was 

established by Executive Order 13995, 

dated January 21, 2021. The Task Force 

is tasked with providing specific 

recommendations to the President, 

through the Coordinator of the COVID– 

19 Response and Counselor to the 

President (COVID–19 Response 

Coordinator), for mitigating the health 

inequities caused or exacerbated by the 

COVID–19 pandemic and for preventing 

such inequities in the future. The Task 

Force shall submit a final report to the 

COVID–19 Response Coordinator 

addressing any ongoing health 

inequities faced by COVID–19 survivors 

that may merit a public health response, 

describing the factors that contributed to 

disparities in COVID–19 outcomes, and 

recommending actions to combat such 

disparities in future pandemic 

responses. 

The meeting is open to the public and 

will be live-streamed at www.hhs.gov/ 

live. No registration is required. A 

public comment session will be held 

during the meeting. Pre-registration is 

required to provide public comment 

during the meeting. To pre-register, 

please send an email to 

COVID19HETF@hhs.gov and include 

your name, title, and organization by 

close of business on Friday, July 23, 

2021. Comments will be limited to no 

more than three minutes per speaker 

and should be pertinent to the meeting 

discussion. Individuals are encouraged 

to provide a written statement of any 

public comment(s) for accurate minutetaking purposes. If you decide you 

would like to provide public comment 

but do not pre-register, you may submit 

your written statement by emailing 

COVID19HETF@hhs.gov no later than 

close of business on Thursday, August 

5, 2021. Individuals who plan to attend 

and need special assistance, such as 

sign language interpretation or other 

reasonable accommodations, should 

contact: COVID19HETF@hhs.gov and 

reference this meeting. Requests for 

special accommodations should be 

made at least 10 business days prior to 

the meeting. 

Dated: July 6, 2021. 

Samuel Wu, 

Designated Federal Officer, COVID–19 Health 

Equity Task Force. 

[FR Doc. 2021–14703 Filed 7–9–21; 8:45 am] 

BILLING CODE 4150–29–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Oligonucleotides 

Analogues Targeting Human LMNA 

‘‘lamin A’’ Gene 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Human Genome 

Research Institute (NHGRI), an institute 

of the National Institutes of Health, 

Department of Health and Human 

Services, is contemplating the grant of 

an Exclusive, Sublicensable Patent 

License to consolidate co-owned rights 

to the inventions and the Patents and 

Patent Applications listed in the 

Supplementary Information section of 

this notice to The Progeria Research 

Foundation (‘‘PRF’’), having a place of 

business in 200 Lake Street, Unit 102, 

Peabody, MA 01960. 

DATES: Only written comments and/or 

applications for a license that are 

received by the NHGRI Office of 

Technology Transfer Office on or before 

July 27, 2021 will be considered. 

ADDRESSES: Requests for a copy of the 

patent application(s), inquiries, and 

comments relating to the contemplated 

license should be directed to: Eggerton 

Campbell, License and Patent Manager, 

NHGRI Technology Transfer Office, 

Telephone: 301–402–1648; email: 

eggerton.campbell@nih.gov. 

SUPPLEMENTARY INFORMATION: The 

following and all continuing U.S. and 

foreign patents/patent applications 

thereof are the intellectual properties to 

be licensed under the prospective 

agreement: 

Country Title Application No. Patent No. 

United States ......... Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–0–US–01.

61/568,590.

WIPO ..................... Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–0–PCT–03.

PCT/US12/068609 

WO 2013/086444.

United Kingdom ..... Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–0–GB–12.

12806796.4 .......... 2788488 

United States ......... Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–0–US–02.

13/708,709 ........... 9,326,992 

United States ......... Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–0–US–06.

15/084,255 ........... 9,833,468 

United States ......... Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–0–US–07.

15/727,483 CON .. 10,398,721 

Europe ................... Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–0–EP–04.

12806796.4 .......... 2788488 

Japan ..................... Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–0–JP–15.

2019–109410.

France .................... Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–0–FR–11.

12806796.4 .......... 2788488 

Germany ................ Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–0–DE–10.

12806796.4 .......... 2788488 

Ireland .................... Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–0–IE–13.

12806796.4 .......... 2788488 

Japan ..................... Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–0–JP–05.

2014–546152 ....... 6132849 

Japan ..................... Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–0–JP–08.

2017–41744.

Netherlands ............ Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–0–NL–14.

12806796.4 .......... 2788488 

Switzerland ............ Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–0–CH–09.

12806796.4 .......... 2788488 

United States ......... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–US–01 ...................................... 62/330,027.

WIPO ..................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–PCT–02 .................................... PCT/US17/30174

WO 2017/190041.


khammond on DSKJM1Z7X2PROD with NOTICES
36564 Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices 

Country Title Application No. Patent No. 

United States ......... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–US–16 ...................................... 16/096,524 (371- 

national phase).

10,822,608 

United States ......... Oligonucleotide Analogues Targeting Human LMNA .................................................................................... 17/024,100.

Australia ................. Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–AU–03 ...................................... 2017258642.

Brazil ...................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–BR–04 ...................................... BR1120180722790.

Canada .................. Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–CA–05 ...................................... 3,022,303.

China ...................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–CN–06 ...................................... 201780040785.7.

Colombia ................ Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–CO–07 ..................................... NC2018/0012783.

Eurasia ................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–EA–08 ...................................... 201892467.

Europe ................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–EP–09 ...................................... 17735676.3.

Hong Kong ............. Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human 

LMNA NIH E–044–2013–1–HK–17.

19126894.5.

India ....................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–IN–10 ....................................... 201847043433.

Japan ..................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–JP–11 ....................................... 2019–508165.

Korea (South) ........ Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–KR–12 ...................................... 10–2018–7034615.

Mexico .................... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–MX–13 ..................................... MX/A/2018/013157.

New Zealand .......... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–NZ–14 ...................................... 747685.

Singapore ............... Oligonucleotide Analogues Targeting Human LMNA NIH E–044–2013–1–SG–15 ...................................... 11201809468X.

The patent rights in these inventions 

have been assigned to the Government 

of the United States of America, the 

University of Maryland, Sarepta 

Therapeutics, Inc, and the Progeria 

Research Foundation (PRF), co-owners 

of said rights, for commercial 

development and marketing. The rights 

to be granted by NHGRI are controlled 

by NHGRI by virtue of co-ownership 

and a license received to the listed 

intellectual property. The prospective 

patent license will be for the purpose of 

consolidating the patent rights to PRF. 

Consolidation of these co-owned rights 

is intended to expedite development of 

the invention, consistent with the goals 

of the Bayh-Dole Act codified as 35 

U.S.C. 200–212. The prospective patent 

license will be worldwide, exclusive, 

may be limited to those fields of use 

commensurate in scope with the patent 

rights, and will be sublicensable. 

The subject technology pertains to 

modified oligonucleotides (called 

phosphorodiamidate morpholino 

oligonucleotides or PMOs) targeted to 

pre-mRNA of human LMNA Lamin A 

gene. These PMOs can be used to 

correct aberrant splicing of LMNA gene 

known to be involved in HutchinsonGilford Progeria Syndrome (HGPS), and 

could be used in treating this ultra-rare 

disease and related laminopathies. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective Exclusive Patent 

License will be royalty bearing and may 

be granted unless, within fifteen (15) 

days from the date of this published 

notice, the NHGRI Technology Transfer 

Office receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404. 

Complete applications for a license 

that are timely filed in response to this 

notice will be treated as objections to 

this to the grant of the contemplated 

exclusive patent license. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information from these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: June 29, 2021. 

Claire T. Driscoll, 

Director, Technology Transfer Office, 

National Human Genome Research Institute, 

National Institutes of Health. 

[FR Doc. 2021–14702 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Mental Health Council. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Mental Health Council. 

Date: August 6, 2021. 

Time: 3:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Tracy Lynn Waldeck, 

Ph.D., Director, Division of Extramural 

Activities, National Institute of Mental 

Health, Neuroscience Center, 6001 Executive 

Boulevard, Room 4133, Rockville, MD 20892, 

(301) 480–6833, waldeckt@mail.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: 

www.nimh.nih.gov/about/advisory-boardsand-groups/namhc/index.shtml, where an 

agenda and any additional information for 

the meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.242, Mental Health Research 

Grants, National Institutes of Health, HHS) 

Dated: July 7, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–14737 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Heart, Lung, 

and Blood Advisory Council. 

The meeting will be closed to the 

public in accordance with the 


khammond on DSKJM1Z7X2PROD with NOTICES